[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"The University of Texas at Arlington\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":300},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,54,76,106,141,167,186,211,239,272],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":33,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100609805","virtual-reality-lethal-means-safety-training-100609805",false,"NCT07219355","Virtual Reality Lethal Means Safety Training","Expanding Provider Capacity to Prevent Rural Veteran Suicide: Virtual Reality Lethal Means Safety Training","Inclusion Criteria:\n\n* Age 18 or older\n* healthcare providers serving rural Veterans in Texas (e.g., physicians, physician assistants, nurse practitioners, nurses, pharmacists, social workers, healthcare case managers)\n* English-speaking\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Self-reported pregnancy\n* History of motor or balance disorders\n* Color blindness\n* Neurological or cognitive disorders\n* Cardiovascular issues that may be worsened by VR use\n* Use of cardiac pacemakers, defibrillators, or hearing aids incompatible with VR equipment\n* Significant discomfort in virtual reality environments (e.g., severe motion sickness, vertigo)",true,"ALL","18 Years",{"count":20,"type":21},36,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this randomized clinical trial is to determine whether a virtual reality (VR) training program can help healthcare providers improve their skills in discussing suicide prevention and safe storage of firearms and medications with Veterans. The study will test whether VR training increases providers' self-efficacy, confidence, and comfort in conducting lethal means safety counseling, and whether it improves their intention to use these counseling practices in their clinical work. Researchers will compare healthcare providers who complete the VR training to those who complete a 2D video training to determine whether the VR approach is more effective. Participants will complete online surveys before and after the training and again three months later. They will be randomly assigned to one of two groups: VR training group: Participants use a VR headset to interact with a virtual Veteran patient in a simulated rural clinic and practice suicide prevention counseling skills; Video training group: Participants use the same headset to watch a \\~10-minute 2D video depicting the lethal means safety counseling session. After the training, participants will also provide feedback about their experience, including how realistic and useful they found the training.",[27,28,29,30,31,32],"Suicide, Attempted","Suicide, Completed","Suicide Prevention","Mental Health Training","Rural Health","Veterans",[32,34,29,35,36,37,38,39,40,31],"Rural Veterans","Suicide Risk","Firearm Safety","Medication Safety","Lethal Means Safety Counseling","Virtual Reality (VR)","VR Training Simulation","RECRUITING","2026-06-23",{"date":44,"type":45},"2026-06-24","ACTUAL",{"date":47,"type":45},"2026-02-23",{"date":49,"type":21},"2026-09-30",{"name":51,"class":52},"The University of Texas at Arlington","OTHER",1,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":4,"eligibilityCriteria":60,"healthyVolunteers":16,"sex":17,"minAge":61,"maxAge":4,"enrollmentInfo":62,"targetDuration":4,"studyType":22,"phases":64,"briefSummary":65,"conditions":66,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":4},"100644268","hybrid-type-1-trial-of-a-parent-based-intervention-addressing-social-media-and-adolescent-alcohol-use-100644268","NCT07664644","Hybrid Type 1 Trial of a Parent-Based Intervention Addressing Social Media and Adolescent Alcohol Use","A Hybrid Type 1 Effectiveness Implementation Trial of a Parent-Based Intervention to Address Social Media Influences on Adolescent Alcohol Outcomes","Parents\u002Flegal guardian inclusion criteria:\n\n* Have a child between the ages of 12-17 who lives with them\n* Believe that their child is active on at least one social media platform\n* Live in Texas\n* Provide a valid email and phone number\n* Own a cell phone with text messaging capabilities and be okay with receiving messages\n* Provide valid contact information for their adolescent\n* Willing to participate in respective phase.\n\nAdolescent inclusion criteria:\n\n* Have an eligible parent with whom they live\n* Age 12-17\n* Live in Texas\n* Active at least weekly on at least one social media platform\n* Provide a valid phone number and email address\n* Own a cell phone with text messaging capabilities and be okay with receiving text messages,\n* Willing to participate in respective phase","12 Years",{"count":63,"type":21},900,[24],"The central goal of this application is to conduct a Hybrid Type 1 effectiveness-implementation randomized controlled trial to test the comparative effectiveness of an alcohol and social media parent-based intervention (PBI), compared to both a combined approach whereby parents receive the alcohol and social media PBI and adolescents receive an alcohol and social media personalized feedback intervention (PFI) and to an efficacious alcohol PBI handbook. Additionally, we will determine key implementation determinants that are crucial to optimizing effectiveness when delivered in community settings. The proposed study will address each of these goals in turn by enrolling parent and adolescent (age 12-17) dyads and collaborating with key community members.",[67],"Adolescent Alcohol Use","NOT_YET_RECRUITING","2026-06-18",{"date":44,"type":45},{"date":72,"type":21},"2027-07",{"date":74,"type":21},"2030-08",{"name":51,"class":52},{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":16,"sex":84,"minAge":18,"maxAge":85,"enrollmentInfo":86,"targetDuration":4,"studyType":22,"phases":88,"briefSummary":89,"conditions":90,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":53},"100482574","exploring-virtual-reality-adventure-training-exergaming-100482574","NCT05563805","Exploring Virtual Reality Adventure Training Exergaming","Exploring Virtual Reality Adventure Training Exergaming (V-RATE) on Veterans' Health Outcomes","V-RATE","Inclusion Criteria:\n\n1. Are between the ages of 18 and 45\n2. Identify as a U.S. military veteran\n\n4\\. Normal vision (no colorblindness)\n\nExclusion Criteria:\n\n1. Unable to walk independently (e.g., use of any mobility assistive device such as brace, wheelchair, cane, crutch, walker, knee scooter)\n2. Self-reported joint problem that limits mobility (e.g., arthritis or other condition that would prevent participation) or ongoing orthopedic injury\n3. Self-reported pregnancy or suspicion of pregnancy\n4. Self-reported motor disorder or impaired sense of motion or balance (such as Parkinsonism)\n5. Self-reported color blindness\n6. Self-reported neurological or cognitive disorder (e.g., TBI, history of seizure)\n7. Self-reported cardiac surgery or any ongoing cardiovascular issues preventing participation or physical activity.","FEMALE","45 Years",{"count":87,"type":21},40,[24],"The current project aims to design and implement an 8-week Virtual Reality Adventure Therapy Exergaming (V-RATE) intervention focused on women veterans. A randomized controlled trial using a repeated measure design with a 1-month follow-up assessment will be employed to examine effects on physical and mental health outcomes.",[91,92,93,94,95,96,97],"Physical Activity","Sedentary Behavior","Depression","Cognitive Function","Post Traumatic Stress Disorder","Quality of Life","Anxiety","2026-05-27",{"date":100,"type":45},"2026-06-01",{"date":102,"type":45},"2022-09-07",{"date":104,"type":21},"2027-08-31",{"name":51,"class":52},{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":16,"sex":17,"minAge":113,"maxAge":114,"enrollmentInfo":115,"targetDuration":4,"studyType":22,"phases":117,"briefSummary":118,"conditions":119,"keywords":128,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":135,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":53},"100479368","reducing-blood-pressure-in-mid-life-adult-binge-drinkers-100479368","NCT05522075","Reducing Blood Pressure in Mid-life Adult Binge Drinkers","Reducing Blood Pressure in Mid-life Adult Binge Drinkers: the Role of Microvascular Function and Sympathetic Activity","Inclusion Criteria:\n\n* Men and women (50-64 years of age) who do not drink alcohol, who drink at moderate levels, or who binge drink\n* Female subjects will be postmenopausal (i.e., cessation of menses for ≥1 yr).\n* Subjects who can speak and understand English.\n\nExclusion Criteria:\n\n* a history of diabetes, cardiovascular disease, liver, or renal disease\n* current or history of smoking and illicit drug use\n* blood pressure ≥160\u002F100 mm Hg\n* other known traditional cardiovascular disease risks: obesity (BMI≥35 kg\u002Fm2), or hyperlipidemia (total cholesterol\\>230 mg\u002Fdl and\u002For LDL cholesterol\\>160 mg\u002Fdl)\n* active infection (in the past 2 months)\n* a history of seizures, cancer, or inflammatory disease (i.e., gout or rheumatoid)\n* unstable body weight (\\>5% change during the past 6 months)\n* regular aerobic exercise training (i.e., they engage in 30 min of structured aerobic exercise at least 3 times per week)\n* current use of hormone replacement therapy (i.e., estrogen, progesterone, and testosterone)","50 Years","64 Years",{"count":116,"type":21},55,[24],"This study has two phases:\n\nPhase 1 is to examine blood pressure, microvascular function, and sympathetic nerve activity in mid-life adult binge drinkers vs. alcohol abstainers\u002Fmoderate drinkers.\n\nPhase 2 is to examine the effect of 8-week aerobic exercise training on blood pressure, microvascular function, and sympathetic nerve activity in mid-life adult binge drinkers",[120,121,122,123,124,125,126,127],"Alcohol Drinking","Binge Drinking","Blood Pressure","Alcohol Abstinence","Aging","Lifestyle Factors","Vasodilation","Behavioral Problem",[129,130,131,132,133,134],"Exercise training","High-intensity interval training","Midlife adults","Middle-aged","Microvascular function","Sympathetic nerve activity",{"date":100,"type":45},{"date":137,"type":45},"2022-11-21",{"date":139,"type":21},"2027-04-30",{"name":51,"class":52},{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":147,"eligibilityCriteria":148,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":149,"enrollmentInfo":150,"targetDuration":4,"studyType":22,"phases":152,"briefSummary":153,"conditions":154,"keywords":156,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":166,"locationsCount":53},"100572029","virtual-reality-infused-treadmill-training-on-aging-related-outcomes-100572029","NCT06727942","Virtual Reality-Infused Treadmill Training on Aging-Related Outcomes","Toward Healthy Living: Virtual Reality-Infused Treadmill Training on Aging-Related Outcomes","V-TARGET","Inclusion Criteria:\n\n1. adults aged up to 75 years old\n2. able to walk independently, without use of an assistive device\n3. English speaking\n\nExclusion Criteria:\n\n1. self-disclosed limited mobility in joint(s) due to arthritis or other condition that would prevent participation\n2. any ongoing orthopedic injury\n3. cardiac surgery or any ongoing cardiovascular issues preventing participation or physical activity.\n4. motor\u002Fcognitive disorders (Alzheimer's disease, Parkinson's disease, dementia, etc.)\n5. use of a wheelchair","75 Years",{"count":151,"type":21},60,[24],"Age-associated motor and cognitive deficits increase the risk of falls, a major cause of morbidity and mortality. Emerging evidence suggests that inflammatory mediators lead to impaired functional capacity and frailty in the elderly and suggests that immune system mediated inflammation in the brain play an important role in cognitive decline. Substantial literature has also demonstrated that age-targeted physical activity training are promising strategies for promoting the motor-cognitive process across the adult lifespan. Recently, the virtual reality (VR) application has been implemented in the neuropsychological rehabilitation settings suggesting that the VR-infused daily living activities may benefit the transfer of intervention outcomes and to promote autonomy in function of daily living such as cooking or grocery shopping. However, it remains unclear the effect of the VR-based exercise intervention (motor-cognitive impact) on older adults' cognitive function and fall prevention. The literature suggests that the similarity of VR exercises with real life activities may improve generalizability by extending the transfer of gains of training to everyday living and promote some aspects of quality of life in older adults. It is also unclear to what extent these aging-associated motor- cognitive changes may be affected by VR rehab games and whether systemic- and neuro-inflammation is ameliorated by this novel intervention in older adults.\n\nThis purpose of this study is to design and implement a Virtual Reality-Infused Treadmill Training on Aging-Related Outcomes (V-TARGET) intervention, focusing on adults (aged up to 75 years old). The study will compare the effects of V-TARGET intervention (self-paced treadmill-simulator exercise with VR rehab games) against a control group on motor-cognitive function, health-related quality of life (HRQOL), circulating inflammatory markers and cerebral\u002Fperipheral blood flow through this 5-week intervention (2 times\u002Fweek, 30-minutes\u002Fsession, 10 sessions total).",[155],"Adult ALL",[157,158,91,159],"Virtual-Reality","Fall Risk Invention","Neuromotor Rehabilitation","2026-05-26",{"date":162,"type":45},"2026-05-29",{"date":164,"type":45},"2022-05-10",{"date":104,"type":21},{"name":51,"class":52},{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":4,"eligibilityCriteria":173,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":174,"enrollmentInfo":175,"targetDuration":4,"studyType":22,"phases":177,"briefSummary":178,"conditions":179,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":181,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":185,"locationsCount":53},"100514052","effects-of-exercise-and-virtual-reality-on-depression-100514052","NCT05973461","Effects of Exercise and Virtual Reality on Depression","Effects of Exercise With Virtual Reality on Females and Males With or Without Depression","Inclusion Criteria:\n\n* Males and females over the age of 18 years\n* With or without symptoms of depression\n* Physically inactive or sedentary (less than 30 minutes per day)\n* Normal vision and no color blindness\n* No physical disorders such as walking with assistance\n\nExclusion Criteria:\n\n* Below the age of 18 years or over 65 years,\n* Women who are pregnant\n* Individuals who have been diagnosed with mental disorders\n* Individuals with leg injuries\n* Individuals with cardiac problems\n* Individuals with a history of asthma\n* Individuals with a body mass index over 30.","65 Years",{"count":176,"type":21},200,[24],"This study is evaluating the effects of riding on a cycle ergometer while experiencing virtual reality to determine its effect on mood.",[180],"Symptoms of Depression",{"date":162,"type":45},{"date":183,"type":45},"2022-05-17",{"date":104,"type":21},{"name":51,"class":52},{"id":187,"slug":188,"hasResults":11,"nctId":189,"briefTitle":190,"officialTitle":191,"acronym":4,"eligibilityCriteria":192,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":193,"enrollmentInfo":194,"targetDuration":4,"studyType":196,"phases":4,"briefSummary":197,"conditions":198,"keywords":199,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":53},"100582020","arlington-aging-study-100582020","NCT06857877","Arlington Aging Study","Arlington Study of Healthy Aging","Inclusion Criteria:\n\nPhase 1: Young healthy men and women between 18 - 30 years of age, and older men and women between 50 - 80 years of age.\n\nPhase 2: Men and women living in Tarrant County, Texas, between 50 - 85 years of age. In addition, the investigators will study up to 120 younger men and women, between 18-30 years of age, equally divided by race\u002Fethnicity (same as above) and sex, to serve as reference controls.\n\nExclusion Criteria:\n\nPhase 1: Clinical diagnosis of dementia; major depression (diagnosed by a physician), visual or auditory impairments that preclude neuropsychological testing or otherwise jeopardize the health and wellbeing of the participant during testing, non-ambulatory status (i.e. less than 10 m without mobility aid), shortness of breath while performing normal activities of daily living (walking through grocery store), body mass index greater than 45 kg\u002Fm2, heart failure or cardiomyopathy, acute coronary syndrome, primary valvular heart disease, severe gait disorder due to musculoskeletal disease or neurological motor deficit (e.g. severe osteoarthritis, lower limb amputation, Parkinson's disease, major stroke with motor sequelae); daily consumption of more than two alcoholic beverages; current treatment for cancer, and estimated life expectancy less than 4 years. Inclusion\u002Fexclusion will be verified using the demographics and medical history.\n\nPhase 2: Clinical diagnosis of dementia; major depression (diagnosed by a physician), visual or auditory impairments that preclude neuropsychological testing or otherwise jeopardize the health and wellbeing of the participant during testing, non-ambulatory status (i.e. less than 10 m without mobility aid), shortness of breath while performing normal activities of daily living (walking through grocery store), body mass index greater than 45 kg\u002Fm2, heart failure or cardiomyopathy, acute coronary syndrome, primary valvular heart disease, severe gait disorder due to musculoskeletal disease or neurological motor deficit (e.g. severe osteoarthritis, lower limb amputation, Parkinson's disease, major stroke with motor sequelae), daily consumption of more than two alcoholic beverages; current treatment for cancer, and estimated life expectancy less than 4 years. Inclusion\u002Fexclusion will be verified using the demographics and medical history.","85 Years",{"count":195,"type":21},770,"OBSERVATIONAL","The goal of this observational study is to learn about the mechanisms causing functional decline with age, using magnetic resonance imaging, exercise science, integrative physiology, neuroscience, and remote monitoring.\n\nSpecific aims include:\n\nAim 1: Advance knowledge of the biology of aging and its impact on the prevention, progression, and prognosis of disease and disability.\n\nAim 2: Determine the effects of personal and societal factors on aging.\n\nAim 3: Examine the influence of racial\u002Fethnic and sex differences on the biology of aging and its impact on the prevention, progression, and prognosis of disease and disability.",[124],[124,200,94,201,202],"MRI","Exercise Science","Remote Monitoring","2026-04-20",{"date":205,"type":45},"2026-04-23",{"date":207,"type":45},"2024-09-01",{"date":209,"type":21},"2030-12-31",{"name":51,"class":52},{"id":212,"slug":213,"hasResults":11,"nctId":214,"briefTitle":215,"officialTitle":216,"acronym":4,"eligibilityCriteria":217,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":218,"targetDuration":220,"studyType":196,"phases":4,"briefSummary":221,"conditions":222,"keywords":224,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":238},"100617037","using-near-infrared-light-to-better-understand-peripheral-artery-disease-100617037","NCT07313410","Using Near-Infrared Light to Better Understand Peripheral Artery Disease","Near-Infrared Diffuse Correlation Spectroscopy to Better Define the Pathophysiology of Peripheral Artery Disease","Inclusion Criteria:\n\n* Cases, Aim 1\n\n  1. 18 or older\n  2. willing to participate under the conditions described in the informed consent form (ICF)\n  3. eligible to sign the ICF\n  4. established diagnosis of PAD confirmed by a physician\n  5. able to comply with the study requirements\n* Cases, Aim 2\n\n  1\\) completed Aim 1\n* Controls 1) asymptomatic, with no history or diagnosis of peripheral artery disease\n\nExclusion Criteria:\n\n* Cases, Aim 1\n\n  1. Ankle-Brachial Index \\>0.9 or \\\u003C0.4\n  2. isolated disease in aorta\u002Filiac vessels\n  3. unstable angina or myocardial infarction in past 12 months\n  4. orthopedic or other physical limitations which would prevent data collection\n  5. contraindications to MRI, including presence of a Pacemaker, presence of bone growth\u002F bone fusion stimulators, presence of tissue expander, presence of cochlear implants, unable to ambulate for 10 feet, receiving continuous Oxygen therapy, pregnancy, permanent Jewelry (screened using MRI safety screening form and verbal screening by MRI operator\n* Cases, Aim 2\n\n  1. unstable angina or myocardial infarction in past 12 months\n  2. orthopedic or other physical limitations which would prevent data collection\n  3. contraindications to MRI, including presence of a pacemaker, presence of bone growth\u002F bone fusion stimulators, presence of tissue expander, presence of cochlear implants, unable to ambulate for 10 feet, receiving continuous Oxygen therapy, pregnancy, permanent Jewelry (screened using MRI safety screening form and verbal screening by MRI operator).\n* Controls 1) history of peripheral artery disease 2) overt cardiovascular disease (e.g. heart failure) 3) known pulmonary disease (excluding mild asthma) 4) current tobacco use 5) orthopedic or other physical limitations which would prevent data collection, 6) BP \\>150\u002F90 mmHg at screening 7) contraindications to MRI, including presence of a pacemaker, presence of bone growth\u002F bone fusion stimulators, presence of tissue expander, presence of cochlear implants, unable to ambulate for 10 feet, receiving continuous Oxygen therapy, pregnancy, permanent Jewelry (screened using MRI safety screening form and verbal screening by MRI operator).",{"count":219,"type":21},120,"6 Months","The goal of this study is to better understand how blood flows and how oxygen is utilized in the lower limbs of people who suffer from peripheral artery disease. This study will also assess how these factors affect treatment outcomes.\n\nSpecific aims include:\n\nAim 1: Utilize BB-NIR-DCS to differentiate PAD patients experiencing primary oxygen delivery limitations from those suffering from mitochondrial dysfunction.\n\nAim 2: Test the efficacy of BB-NIR-DCS at predicting individual responses to vascular intervention.",[223],"Peripheral Artery Disease (PAD)",[225,226,227,228,200,229],"Exercise MRI","Functional Performance","Ankle-Brachial Index","Questionnaires","Peripheral Artery Disease","2025-12-16",{"date":232,"type":45},"2026-01-02",{"date":234,"type":45},"2025-11-01",{"date":236,"type":21},"2028-12-31",{"name":51,"class":52},2,{"id":240,"slug":241,"hasResults":11,"nctId":242,"briefTitle":243,"officialTitle":244,"acronym":4,"eligibilityCriteria":245,"healthyVolunteers":11,"sex":17,"minAge":246,"maxAge":4,"enrollmentInfo":247,"targetDuration":4,"studyType":22,"phases":249,"briefSummary":250,"conditions":251,"keywords":256,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":238},"100608044","asthma-intervention-with-residential-ventilation-and-air-cleaner-airvac-study-100608044","NCT07196436","Asthma Intervention With Residential Ventilation and Air Cleaner (AIRVAC) Study","Energy Recovery Ventilation and Air Cleaner Interventions to Improve Indoor Air Quality, Mold Control, and Asthma-Related Health Outcomes Among Inner-City Children and Adults in Low-Income Households","Inclusion Criteria:\n\n* Individuals with physician-diagnosed asthma, including both adults and children aged 5-17\n* Homeowners living in the DFW metropolitan area, TX\n\nExclusion Criteria:\n\n* Participants living in homes with any smokers","5 Years",{"count":248,"type":21},80,[24],"The primary goal of this study is to investigate the comparative long-term (i.e., 1-year) effectiveness of energy recovery ventilators (ERVs) and portable air cleaners (PACs) in reducing indoor air pollutants and mold levels and improving asthma-related health outcomes in inner-city children and adults with asthma in low-income households in the Dallas-Fort Worth (DFW) metropolitan area, TX. Secondary goals include: (1) examining associations among asthma outcomes, exposure to indoor air pollutants and mold, and housing-related factors, (2) conducting a cost-benefit analysis of ERV and PAC interventions for improving IAQ, mold control, and health outcomes, and (3) evaluating the utility of cost-effective methods and protocols for measuring IAQ and mold for indoor air pollution epidemiology studies and for providing practical information to patients and their physicians. Using a double-blind, placebo-controlled randomized controlled trial, 80 households will be assigned to receive active or placebo versions of ERVs or PACs. Environmental exposures and housing conditions will be monitored alongside comprehensive health assessments, including lung function tests and validated surveys on asthma control, quality of life, stress, and sleep quality.",[252,253,96,254,255],"Asthma Control","Pulmonary Function","Stress","Sleep Quality",[257,252,253,258,96,254,255,259,260,261,262,263],"Asthma","Lung Function","Indoor Air Quality","Residential Ventilation","Air Cleaner","Air Filtration","Mold","2025-10-27",{"date":266,"type":45},"2025-10-29",{"date":268,"type":45},"2025-10-10",{"date":270,"type":21},"2028-02-28",{"name":51,"class":52},{"id":273,"slug":274,"hasResults":11,"nctId":275,"briefTitle":276,"officialTitle":277,"acronym":4,"eligibilityCriteria":278,"healthyVolunteers":11,"sex":17,"minAge":279,"maxAge":280,"enrollmentInfo":281,"targetDuration":4,"studyType":22,"phases":283,"briefSummary":285,"conditions":286,"keywords":288,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":292,"lastUpdatePostDateStruct":293,"startDateStruct":295,"completionDateStruct":297,"leadSponsor":299,"locationsCount":238},"100321916","phase-4-pioglitazone-to-reduce-sympathetic-overactivity-in-ckd-patients-100321916","NCT03471117","Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients","Targeting ADMA With Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients","Inclusion Criteria:\n\n* CKD patients classified as Stage 3 and 4 of National Kidney Foundation Classification with estimated glomerular filtration rate (GFR) between 15 and 59 mL\u002Fmin\u002F1.73 m2 according to the Modification of Diet in Renal Disease (MDRD) formula based on serum creatinine, age, gender, and race.\n* Men and women 35 to 70 years of age\n\nExclusion Criteria:\n\n* Allergy to Glitazones\n* Myocardial infarction\n* Heart failure\n* Angina\n* History of kidney stones\n* Liver disease (abnormal liver enzymes)\n* Anemia (hemoglobin \\\u003C8 g\u002Fdl)\n* Cancer with current treatment\n* Previous organ transplantation\n* Immunosuppressant therapy\n* Human immunodeficiency virus infection\n* Pregnancy or lactating\n* Current tobacco use\n* Dilantin and oral contraceptive usage due to potential drug interaction with glitazones\n* Self-identified history of hypoglycemia","35 Years","70 Years",{"count":282,"type":21},28,[284],"PHASE4","Chronic kidney disease (CKD) is associated with a higher risk of cardiovascular disease and death. An overactive sympathetic nervous system in CKD patients is one of the major mechanisms increasing the cardiovascular risks in this patient population. Recently, some studies have shown that a drug typically used to improve glucose control (pioglitazone) may also reduce sympathetic nerve activity and improve blood vessel function.\n\nThe goal of this study is to determine whether a short-term treatment with pioglitazone can reduce sympathetic nerve impulses throughout the body in CKD patients.",[287],"Chronic Kidney Diseases",[289,290,291],"blood pressure","pioglitazone","hypertension","2025-06-07",{"date":294,"type":45},"2025-06-10",{"date":296,"type":45},"2018-04-01",{"date":298,"type":21},"2026-04-01",{"name":51,"class":52},""]